ImmuCell Corporation
ICCC
$5.19
$0.122.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 51.63% | 46.37% | 48.05% | 32.89% | -5.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.63% | 46.37% | 48.05% | 32.89% | -5.90% |
| Cost of Revenue | 38.77% | 40.10% | 52.51% | 40.76% | 26.57% |
| Gross Profit | 89.89% | 64.43% | 37.84% | 17.58% | -46.63% |
| SG&A Expenses | 8.81% | -2.10% | -0.33% | -5.45% | -4.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.18% | 20.39% | 27.08% | 19.45% | 11.91% |
| Operating Income | 76.38% | 52.70% | 35.90% | 28.03% | -205.32% |
| Income Before Tax | 62.80% | 39.57% | 32.69% | 26.74% | -132.08% |
| Income Tax Expenses | 120.00% | 10.64% | -51.19% | -46.25% | -40.79% |
| Earnings from Continuing Operations | 62.65% | 39.53% | 32.71% | 26.77% | -131.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.65% | 39.53% | 32.71% | 26.77% | -131.56% |
| EBIT | 76.38% | 52.70% | 35.90% | 28.03% | -205.32% |
| EBITDA | 158.07% | 98.42% | 76.03% | 73.30% | -422.02% |
| EPS Basic | 62.31% | 40.31% | 32.93% | 26.78% | -131.53% |
| Normalized Basic EPS | 67.86% | 46.96% | 28.70% | 20.83% | -194.14% |
| EPS Diluted | 61.08% | 38.77% | 31.88% | 25.89% | -132.17% |
| Normalized Diluted EPS | 67.86% | 46.96% | 28.70% | 20.83% | -193.76% |
| Average Basic Shares Outstanding | 5.39% | 1.57% | 0.23% | 0.03% | 0.03% |
| Average Diluted Shares Outstanding | 5.39% | 1.57% | 0.23% | 0.03% | -0.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |